At Peregrine, we are dedicated to supporting and advancing medical innovation through strategic investments. The Peregrine advantage brings together deep industry knowledge and an embedded synergetic strategy. This allows our team of investment professionals to support our portfolio companies in the development of meaningful breakthroughs in healthcare. Whether at an early-stage seed or advanced growth stage, Peregrine’s synergetic approach to investing reaches beyond capital. This allows our firm to provide expert, focused, and concrete services throughout the company lifecycle.
43
Total Investments
31
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Enterprise Software, Pharmaceutical
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Peregrine Ventures
Recent Investments (43)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Seed | •••••• | Jan 2025 | |
| Series D | •••••• | Apr 2024 | |
| Series C | •••••• | Jan 2024 | |
| Venture Round | •••••• | Oct 2023 | |
| Seed Round | •••••• | Oct 2023 | |
|
|
Venture Round | •••••• | Sep 2023 |
|
|
Series A | •••••• | Feb 2023 |
|
|
Series A | •••••• | Nov 2022 |
|
|
Venture Round | •••••• | Jun 2022 |
|
|
Pre Seed Round | •••••• | Mar 2022 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.